Revised Meeting Report
World Parkinson Day Community Workshop
Cedars-Sinai Medical Center, Los Angeles
April 11, 2026
At Cedars-Sinai’s April 11, 2026 Parkinson’s community workshop, speakers stressed that Parkinson’s extends far beyond tremor, spanning motor, non-motor, cognitive, and autonomic symptoms. The program reviewed newer treatments, remote digital monitoring, active clinical trials, atypical parkinsonism, and the growing role of palliative care. A closing presentation emphasized that surgery can help selected arm-and-leg motor symptoms, but not most midline or non-motor problems. Overall, the meeting offered a practical, hopeful roadmap for individualized multidisciplinary care.
Video Archive
https://vimeo.com/1183179155/363e4c2b21?share=copy&fl=sv&fe=ci
The Cedars program director, Dr Tagliati, wrote Parkinson Disease for Dummies, which has excellent reviews.
###
Cedars-Sinai’s Parkinson’s Patient Community Conference was held on Saturday, April 11, 2026, from 9:00 a.m. to 1:30 p.m. as a free hybrid event for patients with Parkinson’s disease and their caregivers. The published faculty included Michele Tagliati, John Mason, Echo Tan, Elliot Hogg, Yvette Bordelon, Jessica Besbris, Adam Mamelak, and Chae Kim. In his opening remarks, Dr. Tagliati noted that this was the 16th consecutive year Cedars-Sinai had organized its patient educational symposium, emphasizing continuity, education, and community support.
The workshop’s central message was that Parkinson’s disease is far more complex than tremor alone. Across the morning, speakers described Parkinson’s as a chronic, fluctuating, multidimensional illness involving motor symptoms, non-motor symptoms, treatment timing, monitoring challenges, research opportunities, atypical syndromes, supportive care needs, and surgical options. The tone was practical and hopeful: the meeting did not promise a cure, but it repeatedly stressed that care is becoming more individualized, data-informed, and multidisciplinary.
Dr. John Mason opened the educational content with a clear overview of the motor symptoms of Parkinson’s disease. He emphasized that Parkinson’s is heterogeneous, meaning patients do not all look alike and do not all share the same dominant symptoms. He reviewed bradykinesia, tremor, rigidity, dystonia, gait changes, freezing of gait, postural changes, postural instability, eye movement abnormalities, speech and swallowing problems, and later-stage dyskinesias. His presentation translated clinical language into daily life: smaller handwriting, difficulty buttoning clothing, reduced arm swing, softer speech, swallowing problems, and falls. He also made the important point that not every patient has major tremor, and that levodopa should not be delayed simply out of fear of dyskinesias, since dyskinesias are more tied to disease progression than to having started the drug “too early.”
Dr. Chae Kim followed with a broad review of non-motor symptoms, arguing that the classic motor picture is only the tip of the iceberg. She highlighted constipation, insomnia, REM sleep behavior disorder, anxiety, depression, apathy, cognitive changes, psychosis, fatigue, urinary symptoms, orthostatic hypotension, and temperature dysregulation. One of her most important points was temporal: several non-motor symptoms can begin years before the motor diagnosis, including constipation, REM sleep behavior disorder, and smell loss. She also emphasized that many patients experience these symptoms as more burdensome than tremor or stiffness. Her treatment discussion was broad and practical, spanning medication choices, sleep studies, bowel regimens, exercise, psychotherapy, attention to mood, and strategies for orthostatic hypotension. In the discussion afterward, she and Dr. Tagliati clarified that orthostatic hypotension is not usually “cured,” but it can often be managed effectively.
Dr. Michele Tagliati then shifted the focus toward digital biomarkers and remote therapeutic monitoring. His core argument was that modern medicine is optimized for acute illnesses, whereas Parkinson’s disease is chronic, variable, and context-dependent, making short office visits a poor fit as the sole basis for decision-making. He pointed to the mismatch between a condition that fluctuates hour to hour and a care model based on a brief office snapshot every few months. He reviewed wearable and app-based systems and highlighted Cedars-Sinai’s pilot experience with smartphone-based monitoring, especially the Neu Health platform. He described a model in which patients perform brief structured tasks through a phone, allowing clinicians to monitor tremor, gait, balance, dexterity, voice, cognition, mood, sleep, pain, blood pressure, medication timing, and symptom fluctuations between visits. His theme was that Parkinson care should become less reactive and more proactive, with continuous information replacing guesswork based on memory alone.
The workshop also included a broader update on clinical research, with Dr. Elliot Hogg presenting what he described as a whirlwind tour of active and emerging Parkinson’s trials. His conclusion was especially notable: he argued that the era of “levodopa-only” thinking is fading, and that the field is moving toward a much broader therapeutic future that includes symptomatic treatments, disease-modifying strategies, wearable-device studies, stem-cell work, and other novel approaches. In the audience discussion, he addressed GLP-1-related research, noting active interest in the field but no currently recruiting California GLP-1 Parkinson trial within the scope he reviewed, while mentioning ongoing or mixed results from trials elsewhere, including liraglutide-related work.
A nice community interlude came next, when the audience was introduced to PCLA, described as a nonprofit built by Parkinson’s patients and care partners, for Parkinson’s patients and care partners. The representative explained that the group provides support groups, informational seminars, and other community resources, including even a comedy show, all aimed at helping patients and families navigate the steep information and support curve of living with Parkinson’s. That moment reinforced that the conference was not just about expert lectures, but also about peer connection and navigation support.
The newly available Part C materially deepens the second half of the meeting.
Dr. Yvette Bordelon spoke on atypical parkinsonism, which she described as the “other part of the Parkinson family” that resembles Parkinson’s disease but differs in mechanism, prognosis, and management. She reviewed the terminology—atypical parkinsonism, Parkinson’s-plus syndromes, and the newer phrase Parkinson’s-like disorders—and stressed that these disorders share parkinsonian motor features such as stiffness and slowness but have important distinguishing characteristics. She specifically identified the four main atypical parkinsonian syndromes as progressive supranuclear palsy, corticobasal degeneration/corticobasal syndrome, multiple system atrophy, and dementia with Lewy bodies, while also noting drug-induced and vascular parkinsonism as related considerations. Her examples were clinically concrete: early falls and eye movement problems in progressive supranuclear palsy, marked asymmetry, apraxia, dystonia, and myoclonus in corticobasal syndrome, and prominent dysautonomia in multiple system atrophy. She also made an important translational point: progress in Parkinson’s research can help atypical syndromes, and vice versa.
Dr. Jessica Besbris then presented on palliative care, a topic she explicitly said is often misunderstood. Her talk was one of the most conceptually important additions in Part C. She pushed back against the idea that palliative care is only for cancer or only for the end of life, and instead defined it as an approach aimed at improving quality of life for patients and families facing serious illness by addressing symptoms, psychosocial and spiritual distress, future planning, and medical decision-making. She described palliative care as a team sport, involving physicians, nurses, advanced practice providers, social workers, chaplains, pharmacists, and others, all working together to support patients and care partners. Her phrase that best captured the talk was that palliative care helps people “live as well as they can for as long as they can.” She emphasized that these needs may begin at diagnosis, not just near death, and may rise and fall over the course of illness.
Dr. Besbris also made the discussion very practical. She explained that in clinic she may talk with patients about what worries them about the future, what they want to plan for, and how to build a kind of roadmap for the course of illness. That roadmap can support discussions about advance healthcare directives, naming a decision-maker, and clarifying what matters most to the patient. Over time, those conversations may extend to major decisions such as feeding tubes, skilled nursing placement, travel as mobility worsens, and, later in illness, transitions to hospice care. Importantly, she did not present this as abstract philosophy. She also summarized evidence that adding palliative care to usual neurological care improves quality of life, decreases symptom burden, including depression, anxiety, constipation, pain, and other non-motor symptoms, reduces caregiver anxiety, and increases completion of future-planning documents. She noted that Cedars has a dedicated neuro-palliative team and described it as part of the institution’s multidisciplinary Parkinson infrastructure.
The final presentation, as you noted, was Dr. Adam Mamelak’s recorded video talk on surgical therapies for Parkinson’s disease. Dr. Mamelak framed surgery not as a cure, but as another form of symptom modulation. He divided treatment into three broad categories: medications, electrical stimulation, and ablative techniques. For the purposes of this talk, he focused mainly on deep brain stimulation (DBS) and focused ultrasound, describing them as the principal surgical modalities currently used day to day. One of the clearest take-home messages from his talk was his simple “arms and legs” rule: surgery tends to help arm- and leg-related motor symptoms such as bradykinesia, rigidity, dystonia, dyskinesia, and tremor, but is much less effective for midline symptoms such as swallowing difficulty, balance impairment, freezing of gait, and certainly not for non-motor symptoms like constipation or sleep problems. That clarification is often exactly what patients need when considering intervention.
He then compared the advantages of the two main surgical strategies. DBS, in his account, is reversible, adjustable, and non-destructive, allowing clinicians to titrate stimulation parameters over time. The tradeoff is that it is still a true surgical procedure, involving implanted hardware and cranial access. By contrast, lesion-based therapies such as focused ultrasound and stereotactic radiosurgery can be rapid, may avoid some traditional surgical risks, and can sometimes be used in older patients or even in those on blood thinners, with symptom relief appearing quickly in some cases. Dr. Mamelak also reviewed the brain targets used for interventional therapy, noting in particular that the ventral intermediate nucleus of the thalamus is a classic target for tremor-dominant disease. Overall, his talk cast surgery as a powerful but selective tool whose value depends heavily on choosing the right patient, the right symptom target, and realistic expectations.
Taken together, the full corrected transcript shows a workshop with a very deliberate arc. It began with recognition of symptoms, moved into monitoring and treatment, widened into research and atypical syndromes, then expanded further into quality of life, planning, caregiver support, and finally surgical intervention. In that sense, the conference did more than teach facts. It modeled a modern Parkinson’s program as something broader than medication management: a system involving specialists, data tools, patient organizations, supportive care, multidisciplinary planning, and selected procedures.
Bottom line: with Part C now included, the conference reads even more clearly as a meeting about the whole Parkinson’s journey. Earlier talks explained the disease and its monitoring; the newly added talks showed how Cedars is also thinking about diagnostic nuance, life planning, caregiver burden, and targeted surgical intervention. The final message was not just that Parkinson’s is treatable, but that care improves when it becomes multidisciplinary, anticipatory, and honest about both possibilities and limits.
I can also turn this into a blog-style article with a 75-word top summary or a cleaner meeting memo format.
